RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

By sjmartinez • February 2, 2024

Nishino K, Shih JY, Nakagawa K, Reck M, Garon EB, Carlsen M, Matsui T, Visseren-Grul C, Nadal E. RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants. JTO Clin Res Rep. 2023 Dec 19;5(2):100624. doi: 10.1016/j.jtocrr.2023.100624. PMID: 38304857; PMCID: PMC10832259.

Tags: Carcinoma, EGFR exon 19 deletion variant, Hematology/Oncology, Non–small cell lung, Publications, ramucirumab, targeted therapy, VEGFR inhibition

Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology

Misic A, Ghanem G, Sadeghi S, Carroll M. Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology. Thromb J.[...]

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences

Bruyat D, Girard N, Heudel P, Penel N, Le Deley MC, Diallo I, Boher JM, Zemmour C, Chanez B, Madroszyk A, Gravis G, Billon E,[...]

Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia

Zuckerman JE, Larson S, Abdelnour L. Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. Kidney Med. 2026 May 12;8(7):101402. doi:[...]